• Je něco špatně v tomto záznamu ?

Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic

P. Jansa, D. Ambrož, M. Kuhn, V. Dytrych, M. Aschermann, V. Černý, V. Gressin, S. Heller, J. Kunstýř, M. Širanec, C. Song, A. Linhart, J. Lindner, A. Muller

. 2022 ; 12 (1) : e12038. [pub] 20220328

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017515

This study investigated the epidemiology and survival outcomes of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic, wherein pulmonary endarterectomy (PEA) surgery was the only targeted treatment option until 2015. This study included all consecutive adults newly diagnosed with CTEPH in the Czech Republic between 2003 and 2016. Incidence/prevalence rates were calculated using general population data extracted from the Institute of Health Information and Statistics of the Czech Republic. Kaplan-Meier estimates of survival from diagnosis until 2018 were calculated. Of a total of 453 patients observed, 236 (52.1%) underwent PEA (median time from diagnosis to PEA: 2.9 months) and 71 (34.1%) had residual pulmonary hypertension (PH) post-PEA. CTEPH incidence rate (95% confidence interval [CI]) between 2006 and 2016 was 4.47 (4.05; 4.91) patients per million (ppm) per year, and the prevalence (95% CI) was 37.43 (33.46; 41.73) ppm in 2016. The rate of CTEPH-related hospitalizations (95% CI) per 100 person-years was 24.4 (22.1; 26.9) for operated patients and 34.2 (30.9; 37.7) for not-operated patients. Median overall survival (95% CI) for all patients from CTEPH diagnosis was 11.2 (9.4; not reached) years. Five-year survival probability (95% CI) was 95.3% (89.9; 97.9) for operated patients without residual PH, 86.3% (75.3; 92.7) for operated patients with residual PH and 61.2% (54.0; 67.6) for not-operated patients. This study reported epidemiological estimates of CTEPH in the Czech Republic consistent with estimates from other national systematic registries; and indicates an unmet medical need in not-operated patients and operated patients with residual PH.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017515
003      
CZ-PrNML
005      
20220720100247.0
007      
ta
008      
220718s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pul2.12038 $2 doi
035    __
$a (PubMed)35506113
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jansa, Pavel $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine Charles University and General University Hospital Prague Czech Republic $1 https://orcid.org/0000000237117064 $7 jo2008427138
245    10
$a Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic / $c P. Jansa, D. Ambrož, M. Kuhn, V. Dytrych, M. Aschermann, V. Černý, V. Gressin, S. Heller, J. Kunstýř, M. Širanec, C. Song, A. Linhart, J. Lindner, A. Muller
520    9_
$a This study investigated the epidemiology and survival outcomes of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic, wherein pulmonary endarterectomy (PEA) surgery was the only targeted treatment option until 2015. This study included all consecutive adults newly diagnosed with CTEPH in the Czech Republic between 2003 and 2016. Incidence/prevalence rates were calculated using general population data extracted from the Institute of Health Information and Statistics of the Czech Republic. Kaplan-Meier estimates of survival from diagnosis until 2018 were calculated. Of a total of 453 patients observed, 236 (52.1%) underwent PEA (median time from diagnosis to PEA: 2.9 months) and 71 (34.1%) had residual pulmonary hypertension (PH) post-PEA. CTEPH incidence rate (95% confidence interval [CI]) between 2006 and 2016 was 4.47 (4.05; 4.91) patients per million (ppm) per year, and the prevalence (95% CI) was 37.43 (33.46; 41.73) ppm in 2016. The rate of CTEPH-related hospitalizations (95% CI) per 100 person-years was 24.4 (22.1; 26.9) for operated patients and 34.2 (30.9; 37.7) for not-operated patients. Median overall survival (95% CI) for all patients from CTEPH diagnosis was 11.2 (9.4; not reached) years. Five-year survival probability (95% CI) was 95.3% (89.9; 97.9) for operated patients without residual PH, 86.3% (75.3; 92.7) for operated patients with residual PH and 61.2% (54.0; 67.6) for not-operated patients. This study reported epidemiological estimates of CTEPH in the Czech Republic consistent with estimates from other national systematic registries; and indicates an unmet medical need in not-operated patients and operated patients with residual PH.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ambrož, David $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine Charles University and General University Hospital Prague Czech Republic
700    1_
$a Kuhn, Matyáš $u Data Analysis Department Institute of Biostatistics and Analysis Brno Czech Republic
700    1_
$a Dytrych, Vladimír $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine Charles University and General University Hospital Prague Czech Republic
700    1_
$a Aschermann, Michael $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine Charles University and General University Hospital Prague Czech Republic
700    1_
$a Černý, Vladimír $u Department of Radiology, First Faculty of Medicine Charles University and General University Hospital Prague Czech Republic
700    1_
$a Gressin, Virginie $u Actelion Pharmaceuticals Ltd. Allschwil Switzerland
700    1_
$a Heller, Samuel $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine Charles University and General University Hospital Prague Czech Republic
700    1_
$a Kunstýř, Jan $u Department of Anesthesiology and Intensive Care, First Faculty of Medicine Charles University and General University Hospital Prague Czech Republic
700    1_
$a Širanec, Michal $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine Charles University and General University Hospital Prague Czech Republic
700    1_
$a Song, Ci $u Janssen Pharmaceutical Companies of Johnson & Johnson Solna Sweden
700    1_
$a Linhart, Aleš $u 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine Charles University and General University Hospital Prague Czech Republic
700    1_
$a Lindner, Jaroslav $u 2nd Department of Surgery, Department of Cardiovascular Surgery Charles University and General University Hospital Prague Czech Republic
700    1_
$a Muller, Audrey $u Actelion Pharmaceuticals Ltd. Allschwil Switzerland
773    0_
$w MED00200184 $t Pulmonary circulation $x 2045-8932 $g Roč. 12, č. 1 (2022), s. e12038
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35506113 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100243 $b ABA008
999    __
$a ind $b bmc $g 1816625 $s 1168757
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 12 $c 1 $d e12038 $e 20220328 $i 2045-8932 $m Pulmonary circulation $n Pulm Circ $x MED00200184
LZP    __
$a Pubmed-20220718

Najít záznam

Citační ukazatele

Možnosti archivace